share_log

Needham Reiterates Buy on Autolus Therapeutics, Maintains $7 Price Target

Benzinga ·  Nov 29, 2023 05:50

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment